GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Price-to-Owner-Earnings
Switch to:

Biogen (MEX:BIIB) Price-to-Owner-Earnings

: 19.21 (As of Today)
View and export this data going back to 2013. Start your Free Trial

As of today (2023-03-21), Biogen's share price is MXN4991.71. Biogen's Owner Earnings per Share (TTM) ended in Dec. 2022 was MXN259.88. It's Price-to-Owner-Earnings for today is 19.21.


The historical rank and industry rank for Biogen's Price-to-Owner-Earnings or its related term are showing as below:

MEX:BIIB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.28   Med: 21.04   Max: 4222.78
Current: 19.21

During the past 13 years, the highest Price-to-Owner-Earnings of Biogen was 4222.78. The lowest was 7.28. And the median was 21.04.


MEX:BIIB's Price-to-Owner-Earnings is ranked better than
56.6% of 424 companies
in the Drug Manufacturers industry
Industry Median: 22.08 vs MEX:BIIB: 19.21

As of today (2023-03-21), Biogen's share price is MXN4991.71. Biogen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was MXN418.87. Therefore, Biogen's PE Ratio for today is 11.92.

As of today (2023-03-21), Biogen's share price is MXN4991.71. Biogen's EPS without NRI for the trailing twelve months (TTM) ended in was MXN418.87. Therefore, Biogen's PE Ratio without NRI for today is 11.92.

During the past 13 years, Biogen's highest PE Ratio without NRI was 40.88. The lowest was 7.58. And the median was 19.02.


Biogen Price-to-Owner-Earnings Historical Data

The historical data trend for Biogen's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.62 9.25 10.68 53.01 19.85

Biogen Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.01 84.08 13.20 11.92 19.85

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen Price-to-Owner-Earnings Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Biogen's Price-to-Owner-Earnings falls in comparison to its industry or sector. The grey bar indicates the Price-to-Owner-Earnings's extreme value range as defined by GuruFocus.



Biogen Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Biogen's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=4991.71/259.88
=19.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (MEX:BIIB) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Biogen Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Biogen's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines

Other Sources